Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OxSENSE: Semaglutide Effects on Cognition and Energy
NCT06363487Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Jun 2024
- Primary completion
- Dec 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in depressive disorders comparing Semaglutide with Placebo (2 arms). Primary endpoints: Reward (learning), Reward (effort-based) and 1 more. Started Jun 2024; status: completed.
02
Drugs
03
Conditions
depressive disorders
Beyond the preview
Go deeper on NCT06363487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06363487.